In this study, we demonstrate that CAR-GPC3-NK cells exhibit potent, specific anti-tumor activity, suggesting their potential as a synergistic clinical option, alongside targeting checkpoint inhibitors [71]. The gene discussed is GPC3; the disease is neoplasm.